Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Fatty Acids in Autoimmune Disorders: Evidence Overview

Fatty acids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential role in modulating immune function and inflammation in autoimmune disorders. Scientific interest is based on their anti-inflammatory properties, which may be beneficial in conditions characterized by chronic inflammation, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS).

Clinical trials have provided moderate evidence supporting the use of omega-3 fatty acids—primarily from fish oil supplementation—in reducing disease activity and improving symptoms in RA. For instance, several randomized controlled trials (RCTs) and meta-analyses have found that omega-3 supplementation can reduce joint pain and morning stiffness in RA. However, the effects are generally modest and not universal.

The evidence for other autoimmune diseases is less robust. Some studies in SLE and MS suggest possible beneficial immunomodulatory effects, but results are inconsistent and often limited by small sample sizes and methodological differences. Importantly, omega-3 fatty acids are considered safe and well-tolerated, which supports their adjunctive use, though they are not a replacement for standard therapies.

Overall, while there is scientific validation for the use of fatty acids, especially omega-3s, in supporting management of certain autoimmune disorders—primarily RA—the evidence is moderate (rated 3) and more research is needed for broader recommendations.

More about Fatty acids
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Fatty acids

Products containing Fatty acids